OCGN
Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and
Monday, September 30, 2019 1 min read
Key Takeaway: Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck
Orphan us oGVHD OCU300 NR2f3 Mutation-Associated Retinal Degeneration Orphan us CfP290 Mutation-Associated Retinal Degeneration Orphan us OCU400 NIVI-?-AAV Rhodopsin Mutation
Full Press Release Details
Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck
Orphan us oGVHD OCU300 NR2f3 Mutation-Associated Retinal Degeneration Orphan us CfP290 Mutation-Associated Retinal Degeneration Orphan us OCU400 NIVI-?-AAV Rhodopsin Mutation-Associated Retinal Degeneration OCU410 RO!<-IMV DryAMD > WetAMD > OCU200 tiiTl ld.l " Tr no;,f<'p in Diabetic Macular Edema > Diabetic Retinopathy OCU100 Retinitis Pigmentosa . ocugen 2019 Ocugen.AII Rights Reserved. RETINAL DISEASES (novel biologics) MODIFIER GENE THERAPY PLATFORM OCULAR SURFACE DISEASE (small molecule) Phase 3 Phase 2 Phase 1 Preclinical Indication